TY - JOUR
T1 - A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
AU - Suzuki, R.
AU - Hasegawa, Y.
AU - Baba, K.
AU - Saka, H.
AU - Saito, H.
AU - Taniguchi, H.
AU - Yamamoto, M.
AU - Matsumoto, S.
AU - Kato, K.
AU - Oishi, T.
AU - Imaizumi, K.
AU - Shimokata, K.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/6/5
Y1 - 2006/6/5
N2 - The aim of this study was to evaluate the efficacy and tolerability of gefitinib ('IRESSA') in Japanese patients with previously untreated stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously untreated stage IV NSCLC were enrolled between May 2003 and September 2004. Gefitinib was administered orally 250mg once a day and was continued until there was either disease progression or severe toxicity. Objective tumour response rate was 26.5% (95% confidence interval, 11.7-41.3%). Adverse events were generally mild (National Cancer Institute-Common Toxicity Criteria grade 1 or 2) and consisted mainly of skin rash, fatigue and liver dysfunction. No pulmonary toxicity was observed. The global health status revealed that there was no change in quality of life during the study. This study found that single-agent gefitinib is active and well tolerated in chemonaive Japanese patients with advanced NSCLC.
AB - The aim of this study was to evaluate the efficacy and tolerability of gefitinib ('IRESSA') in Japanese patients with previously untreated stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously untreated stage IV NSCLC were enrolled between May 2003 and September 2004. Gefitinib was administered orally 250mg once a day and was continued until there was either disease progression or severe toxicity. Objective tumour response rate was 26.5% (95% confidence interval, 11.7-41.3%). Adverse events were generally mild (National Cancer Institute-Common Toxicity Criteria grade 1 or 2) and consisted mainly of skin rash, fatigue and liver dysfunction. No pulmonary toxicity was observed. The global health status revealed that there was no change in quality of life during the study. This study found that single-agent gefitinib is active and well tolerated in chemonaive Japanese patients with advanced NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=33745230152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745230152&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6603159
DO - 10.1038/sj.bjc.6603159
M3 - Article
C2 - 16670714
AN - SCOPUS:33745230152
VL - 94
SP - 1599
EP - 1603
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 11
ER -